

R1 R2 R3 PG0 PG1 Estagiário Tecnólogo
PIBIC Last Name - Bordon First Name - Priscilla Middle - Ballalai

Service (sector) Tumors and Pathology N° CEP

Topical Mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia

Priscilla Ballalai Bordon Clélia M. Erwenne Walter K. Fukumoto Purpose: To evaluate the use of topical Mitomycin C (MMC) chemotherapy in the treatment of conjunctival melanoma and PAM with atypia.

Methods: Patients with conjunctival melanoma or conjunctival melanoma and PAM with atypia were treated with topical MMC 0,02% qid, for 3 to 4 weeks as an adjuvant treatment or to treat residual disease. These patients have been followed weekly during the treatment and every three months subsequently. Biopsy was done in 3 patients with diffuse disease after the treatment, as a control.

Results: Eight patients were treated. Five had conjunctival melanoma and PAM with atypia and used MMC after surgical excision to treat residual disease. Three had only conjunctival melanoma and used MMC after excision in effort to improve local control. Two patients with PAM had total regression of the pigmentation, and underwent a biopsy, which showed no atypias. In all patients there was good local control without recurrence of the tumor in a mean follow-up of 22,6 months. One patient had lymph node metastasis one year after treatment.

Conclusion: In this group of patients, the use of topical MMC chemotherapy was efficient to treat PAM with atypia and to prevent local recurrences of conjunctival melanoma, although it did not prevent distant metastasis.